Optimer begins fidaxomicin rolling NDA

Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) began submission of a rolling NDA to FDA for fidaxomicin to treat Clostridium difficile infection (CDI) and to prevent recurrences of CDI. The company plan...